Please try another search
For the six months ended 30 June 2021, Translate BioInc revenues increased from $21M to $107.2M. Net incometotaled $43.7M vs. loss of $50.6M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net Income reflectsChange in fair value of contingent consi decrease from$5.9M (expense) to $39.7M (income), Stock-basedCompensation in R&D decrease of 11% to $4.9M (expense).
Period Ending: | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
---|---|---|---|---|
Total Revenue | 72.65 | 34.6 | 51.39 | 66.45 |
Gross Profit | ||||
Operating Income | 16.01 | 26.62 | -20.64 | 16.75 |
Net Income | 17.14 | 26.52 | -20.56 | 17.34 |
Period Ending: | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
---|---|---|---|---|
Total Assets | 904.87 | 890.64 | 889.94 | 908.63 |
Total Liabilities | 492.23 | 501.75 | 533.18 | 542.96 |
Total Equity | 412.64 | 388.89 | 356.76 | 365.67 |
Period Ending: | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | 13.69 | 0.69 | 236.32 | 258.29 |
Cash From Investing Activities | -109.11 | -188.52 | -215.12 | 97.92 |
Cash From Financing Activities | 2.86 | 1.55 | 240.13 | 233.26 |
Net Change in Cash | -92.56 | -186.28 | 261.32 | 589.47 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review